-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
There is currently no effective treatment for Coronary Viral Disease (Covid-19) in 2019, and Redsyvir is once the industry's most highly expected drug.
recently published the final results of a clinical study of Redsiway's treatment of new coronary pneumonia.
In this double-blind, randomized, placebo-controlled study, researchers recruited adult patients hospitalized with Covid-19 with lower respiratory tract infections to be randomly intravenously injected with Redsywe (200 mg on the first day of load, followed by a daily therapeutic dose of 100 mg for up to 9 days) or a placebo.
result of this study is recovery time, defined as discharge or hospitalization for infection control purposes only.
1,062 patients were involved in the study, including 541 in the Redsiway group and 521 in the placebo group.
recovery time for patients receiving Redsyve treatment was 10 days, while for patients receiving placebo was 15 days (recovery rate was 1.29).
analysis showed that patients treated with Redsiway were more likely to experience clinical improvement on the 15th day (the actual disease severity-adjusted advantage was 1.5) than placebo.
survival analysis showed a 15-day mortality rate of 6.7 per cent in the Redsyway group, 11.9 per cent in the placebo group, 11.4 per cent on the 29th day in the Redsyve group and 15.2 per cent in the placebo (risk ratio of 0.73).
131 (24.6%) of the 532 patients treated with Redsiway reported serious adverse events, and 163 (31.6%) of the 516 patients treated with placebo reported serious adverse events.
that in patients with new coronary pneumonia with evidence of lower respiratory tract infections, redsiway therapy is beneficial in reducing recovery time.
.